Mortalité et facteurs pronostiques du myxofibrosarcome — analyse rétrospective de 109 patients

Abstract Background Myxofibrosarcoma (MFS) is one of the most common sarcoma subtype in elderly patients. They are reported to recur locally independently of the tumour grade in 30–40% of cases and metastases are reported to develop in high-grade tumours in 20–35% cases. As MFS is a rare diagnosis, data investigating specific survival and independent risk factors are lacking and have mostly been limited to single orthopaedic oncology centre studies so far. Thus we set up a pathology-based retrospective study and analyzed all MFS diagnosed in our institution with the following aims: (1) analysis of independent risk factors for overall survival, disease specific survival, local recurrence-free survival and distant metastasis free survival following resection of MFS and (2) analysis of resection margin status. Hypothesis High-grade MFS have a low survival distant metastasis free survival and local recurrence-free survival is dependent on surgical margin status. Patients and methods We retrospectively analysed 109 patients (median 66 years [range, 21–96]) diagnosed with MFS and a median follow-up of 42 months at one centre between 1990 and 2014. Tumor-associated survival, including competing risk analysis, and prognostic factors for local recurrence, metastatic disease and death from disease were investigated and included in a multivariate analysis. Results Overall survival was 79% [95% CI: 71.9–87.5] at 3 years and 76% [95% CI: 67.4–84.6] at 5 years. Disease specific survival was 85% [95% CI: 78.4–92.2] at 3 years and 80% [95% CI: 72.2–88.2] at 5 years. There were local recurrences in 11/109 patients (10%). Local recurrence-free survival (LRFS) was 95% [95% CI: 92.0–99.8] at 3 and 88% [95% CI: 84.3–96.4] at 5 years. Metastatic disease (n = 25; 23%) occurred after a median follow-up of 10 months. Distant metastasis free survival was 78% [95% CI: 69.9–85.9] at 3 and 77% [95% CI: 68.4–84.8] at 5 years. R1 status at primary resection was an independent risk factor for decreased local recurrence-free survival (OR: 8.5, 95% CI: 1.59–49.79 [p = 0.01]). Grading was an independent risk factor for decreased disease specific survival (OR 13.4, 95% CI: 1.65–1734.84 [p = 0.01]) and distant metastasis free survival (OR 16.2, 95% CI: 2.0–2110.5 [p = 0.004]). Primary resection achieved R0 margins in 63 (58%) of 109 patients. Margins were adequate significantly more often (p  Discussion Patients with high-grade MFS had a poorer prognosis with respect to Disease specific survival/Distant metastasis free survival than low-grade MFS. Local recurrence did not significantly affect disease specific survival. Level of evidence IV.